|By PR Newswire||
|March 22, 2013 08:00 AM EDT||
MISSISSAUGA, ON, March 22, 2013 /CNW/ - PATHOS is the largest real-world study to compare the effectiveness of two commonly prescribed inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination treatments for chronic obstructive pulmonary disease (COPD) with more than one year of patient follow-up.1 An analysis of PATHOS data shows that COPD patients treated with SYMBICORT® (budesonide/formoterol) are significantly less likely to suffer from COPD-related exacerbations - or 'flare ups' - and are significantly less likely to be hospitalized for COPD than those treated with ADVAIR® (fluticasone/salmeterol).1
Overall, SYMBICORT® reduced the annual rate of moderate to severe exacerbations by 26 per cent compared to ADVAIR® (0.80 vs. 1.09 /patient-year; p<0.0001).1 The significant and clinically relevant reduction in favour of SYMBICORT® was apparent for all types of exacerbation events (e.g. antibiotic use, oral steroid use or hospital admission).1 Indeed, use of SYMBICORT® reduced rates of COPD-related hospitalization by 29 per cent (0.15 vs. 0.21 /patient-year; p<0.0001) with hospital days due to COPD exacerbation 34 per cent fewer (0.63 vs. 0.95/patient-year; p<0.0001) compared with ADVAIR®.1 This analysis of the PATHOS data was recently published in the Journal of Internal Medicine.1
"COPD is rapidly becoming one of the world's most serious health issues and is the fourth leading cause of death in Canada," said Dr. Charlie Chan, Professor and Vice-Chair of Medicine, University of Toronto, consultant Respirologist, University Health Network. "As a real-world evidence study, PATHOS plays an important role in helping healthcare professionals understand the impact of COPD treatment options on patient outcomes, and coupled with rigorous clinical trial data analysis, can provide a more fulsome picture of disease patterns patients are experiencing."
The 11-year PATHOS study, led by Uppsala University, retrospectively examined the medical records of 5,468* ICS/LABA-treated patients in Sweden from 1999 to 2009; comprising a total of 19,000 patient years.1 This first published analysis of the data compares the rate of COPD exacerbations associated with two commonly prescribed combinations.1 To allow for a valid comparison, a cohort of patients treated with SYMBICORT® were individually matched with an equal number of patients treated with a second ICS/LABA, ADVAIR®.1 Investigators used a statistical technique called "propensity score matching" to minimize bias and ensure the two ICS/LABA-treated groups were comparable in terms of variables including age, gender and measures of disease severity such as medication use, COPD co-morbidities, previous hospitalizations for any cause and exacerbation rates for COPD and other conditions like respiratory infections prior to the first ICS/LABA prescription.1 Exacerbations were defined in the study as medical interventions such as hospitalizations, emergency room visits and prescription of oral steroids or antibiotics due to COPD deterioration.1
The exacerbation findings published today are the first of several analyses of the PATHOS data. As a real-world evidence study, the findings show the impact of the two treatment combinations in clinical practice, providing healthcare providers, patients and payers with valuable information that can be used to inform their treatment decisions. PATHOS also collected data regarding rates of pneumonia events as the comparative safety measure, the evolution of COPD care during the 11-year period and how access to an asthma or COPD nurse impacts care. Analyses of these data are expected in subsequent publications.
COPD encompasses two serious lung diseases - emphysema and chronic bronchitis - which result in chronic airway inflammation and progressive loss of lung function, making it difficult to breathe normally.2 Common symptoms of COPD include breathlessness, sputum and chronic cough.2 People with COPD are likely to experience COPD exacerbations, an acute worsening of symptoms that are a key driver of increased mortality and have been linked to a decline in lung function and worsening overall health.3 Over 750,000 Canadians have been diagnosed with COPD and as many as 1.6 million more people may have COPD, but remain undiagnosed.4 COPD already kills more people worldwide than cancer 5 and is the fourth leading cause of death in Canada, causing approximately 10,000 deaths a year.6
PATHOS is a real-world, retrospective study that examined the medical records of 21,361 COPD patients (of which 5,468 were medically matched) over an 11-year period in Sweden to better understand the evolution of COPD care and the impact of different COPD management strategies on outcomes for patients.1 It is the largest and longest real-world study to compare the effectiveness and safety of two commonly prescribed ICS/LABA combination treatments for COPD. Medical records' data was linked to national, mandatory Swedish healthcare registries, including hospital, drug and cause of death register data for 1999-2009, and analyzed by Uppsala University to provide high-quality evidence of outcomes in a real-world setting.1
About Real-World Evidence
Unlike randomized, controlled clinical trials, real-world evidence studies use observational data, such as electronic medical records and healthcare registries, to create deeper insights into unmet clinical need, the burden of illness, the cost of care or the actual, rather than expected, impact of management strategies or treatments in a real world setting. AstraZeneca is committed to understanding the impact of its medicines in the real-world, beyond what is seen in controlled clinical trials. These insights will help AstraZeneca develop medicines that improve the treatment of disease and help inform healthcare decision-making to ensure effective use of medicines that minimize the burden on patients and healthcare budgets.
About SYMBICORT® (budesonide/formoterol)
SYMBICORT® (budesonide/formoterol) provides both the anti-inflammatory corticosteroid budesonide and the rapid and long-lasting bronchodilator formoterol in the same device - the SYMBICORT® Turbuhaler®. SYMBICORT® (budesonide/formoterol) is indicated for the treatment of COPD in 88 countries worldwide.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca's Canadian headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.
|1.||Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease. The PATHOS study. Journal of Internal Medicine. Available from: http://onlinelibrary.wiley.com/doi/10.1111/joim.12067/abstract. Last accessed March 19, 2013.|
|2.||World Health Organization (WHO). COPD Fact Sheet Number 315. Available from: http://www.who.int/mediacentre/factsheets/fs315/en/index.html. Last accessed January 17, 2013.|
|3.||Papi A et al. Pathophysiology of Exacerbations of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2006; 3:245-251.|
|4.||The Lung Association. The Challenge of Lung Disease in Canada. Available from: http://www.lung.ca/involved-impliquez/federalelection-electionfederale/background-contexte/index_e.php#s4 . Last accessed February 20, 2013.|
|5.||World Health Organization (WHO). The Global Burden of Disease. 2004 Update. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Last accessed January 17, 2013.|
|6.||BC Medical Journal. A Snapshot of Chronic Obstructive Pulmonary Disease in British Columbia and Canada. Available from: http://www.bcmj.org/article/snapshot-chronic-obstructive-pulmonary-disease-british-columbia-and-canada. Last accessed February 20, 2013.|
*9,893 ICS/LABA-treated patient records were analyzed and propensity-matched, a common means of balancing study groups to minimize bias when randomization is not possible or appropriate. Matching of these 9,893 patients (7,155 budesonide/formoterol; 2,738 fluticasone/salmeterol) yielded two matched cohorts each of 2,734 patients.1
SOURCE AstraZeneca Canada Inc.
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
Oct. 22, 2016 05:00 AM EDT Reads: 654
SYS-CON Events announced today that Pulzze Systems will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems, Inc. provides infrastructure products for the Internet of Things to enable any connected device and system to carry out matched operations without programming. For more information, visit http://www.pulzzesystems.com.
Oct. 22, 2016 05:00 AM EDT Reads: 2,465
In the next forty months – just over three years – businesses will undergo extraordinary changes. The exponential growth of digitization and machine learning will see a step function change in how businesses create value, satisfy customers, and outperform their competition. In the next forty months companies will take the actions that will see them get to the next level of the game called Capitalism. Or they won’t – game over. The winners of today and tomorrow think differently, follow different...
Oct. 22, 2016 04:30 AM EDT Reads: 795
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
Oct. 22, 2016 03:30 AM EDT Reads: 1,662
The Open Connectivity Foundation (OCF), sponsor of the IoTivity open source project, and AllSeen Alliance, which provides the AllJoyn® open source IoT framework, today announced that the two organizations’ boards have approved a merger under the OCF name and bylaws. This merger will advance interoperability between connected devices from both groups, enabling the full operating potential of IoT and representing a significant step towards a connected ecosystem.
Oct. 22, 2016 02:45 AM EDT Reads: 1,148
SYS-CON Events announced today that Interface Masters Technologies, a leader in Network Visibility and Uptime Solutions, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading vendor in the network monitoring and high speed networking markets. Based in the heart of Silicon Valley, Interface Masters' expertise lies in Gigabit, 10 Gigabit and 40 Gigabit Eth...
Oct. 22, 2016 02:45 AM EDT Reads: 3,285
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his session at @DevOpsSummit 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will show how customers are able to achieve a level of transparency that enables everyon...
Oct. 22, 2016 02:45 AM EDT Reads: 1,243
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and microservices. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your conta...
Oct. 22, 2016 02:00 AM EDT Reads: 1,390
DevOps theory promotes a culture of continuous improvement built on collaboration, empowerment, systems thinking, and feedback loops. But how do you collaborate effectively across the traditional silos? How can you make decisions without system-wide visibility? How can you see the whole system when it is spread across teams and locations? How do you close feedback loops across teams and activities delivering complex multi-tier, cloud, container, serverless, and/or API-based services?
Oct. 22, 2016 01:45 AM EDT Reads: 942
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
Oct. 22, 2016 01:30 AM EDT Reads: 9,608
SYS-CON Events announced today that Streamlyzer will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Streamlyzer is a powerful analytics for video streaming service that enables video streaming providers to monitor and analyze QoE (Quality-of-Experience) from end-user devices in real time.
Oct. 22, 2016 01:15 AM EDT Reads: 890
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
Oct. 22, 2016 01:15 AM EDT Reads: 808
@ThingsExpo has been named the Top 5 Most Influential Internet of Things Brand by Onalytica in the ‘The Internet of Things Landscape 2015: Top 100 Individuals and Brands.' Onalytica analyzed Twitter conversations around the #IoT debate to uncover the most influential brands and individuals driving the conversation. Onalytica captured data from 56,224 users. The PageRank based methodology they use to extract influencers on a particular topic (tweets mentioning #InternetofThings or #IoT in this ...
Oct. 22, 2016 01:00 AM EDT Reads: 8,150
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 7-9, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and ...
Oct. 22, 2016 12:30 AM EDT Reads: 3,492
Today every business relies on software to drive the innovation necessary for a competitive edge in the Application Economy. This is why collaboration between development and operations, or DevOps, has become IT’s number one priority. Whether you are in Dev or Ops, understanding how to implement a DevOps strategy can deliver faster development cycles, improved software quality, reduced deployment times and overall better experiences for your customers.
Oct. 22, 2016 12:30 AM EDT Reads: 520